

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT												
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY												
CONVEYING PARTY DATA													
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="text-align: center;">Name</th> <th style="text-align: center;">Formerly</th> <th style="text-align: center;">Execution Date</th> <th style="text-align: center;">Entity Type</th> </tr> <tr> <td>Credit Suisse AG</td> <td>FORMERLY Credit Suisse First Boston</td> <td>01/31/2011</td> <td>bank: SWITZERLAND</td> </tr> </table>	Name	Formerly	Execution Date	Entity Type	Credit Suisse AG	FORMERLY Credit Suisse First Boston	01/31/2011	bank: SWITZERLAND					
Name	Formerly	Execution Date	Entity Type										
Credit Suisse AG	FORMERLY Credit Suisse First Boston	01/31/2011	bank: SWITZERLAND										
RECEIVING PARTY DATA													
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td>Name:</td><td>Parkedale Pharmaceuticals, Inc.</td></tr> <tr><td>Street Address:</td><td>870 Parkedale Road</td></tr> <tr><td>City:</td><td>Rochester</td></tr> <tr><td>State/Country:</td><td>MICHIGAN</td></tr> <tr><td>Postal Code:</td><td>48307</td></tr> <tr><td>Entity Type:</td><td>CORPORATION: MICHIGAN</td></tr> </table>	Name:	Parkedale Pharmaceuticals, Inc.	Street Address:	870 Parkedale Road	City:	Rochester	State/Country:	MICHIGAN	Postal Code:	48307	Entity Type:	CORPORATION: MICHIGAN	
Name:	Parkedale Pharmaceuticals, Inc.												
Street Address:	870 Parkedale Road												
City:	Rochester												
State/Country:	MICHIGAN												
Postal Code:	48307												
Entity Type:	CORPORATION: MICHIGAN												
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td>Name:</td><td>King Pharmaceuticals, Inc.</td></tr> <tr><td>Street Address:</td><td>501 Fifth Street</td></tr> <tr><td>City:</td><td>Bristol</td></tr> <tr><td>State/Country:</td><td>TENNESSEE</td></tr> <tr><td>Postal Code:</td><td>37620</td></tr> <tr><td>Entity Type:</td><td>CORPORATION: TENNESSEE</td></tr> </table>	Name:	King Pharmaceuticals, Inc.	Street Address:	501 Fifth Street	City:	Bristol	State/Country:	TENNESSEE	Postal Code:	37620	Entity Type:	CORPORATION: TENNESSEE	
Name:	King Pharmaceuticals, Inc.												
Street Address:	501 Fifth Street												
City:	Bristol												
State/Country:	TENNESSEE												
Postal Code:	37620												
Entity Type:	CORPORATION: TENNESSEE												
PROPERTY NUMBERS Total: 3													
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="text-align: center;">Property Type</th> <th style="text-align: center;">Number</th> <th style="text-align: center;">Word Mark</th> </tr> <tr> <td>Registration Number:</td> <td>2015950</td> <td>PROCANBID</td> </tr> <tr> <td>Registration Number:</td> <td>2065975</td> <td>PROCANBID</td> </tr> <tr> <td>Registration Number:</td> <td>2062311</td> <td>PROCANBID</td> </tr> </table>	Property Type	Number	Word Mark	Registration Number:	2015950	PROCANBID	Registration Number:	2065975	PROCANBID	Registration Number:	2062311	PROCANBID	
Property Type	Number	Word Mark											
Registration Number:	2015950	PROCANBID											
Registration Number:	2065975	PROCANBID											
Registration Number:	2062311	PROCANBID											
CORRESPONDENCE DATA													
Fax Number: (202)778-5299 <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i> Phone: 202.662.5299 Email: trademarks@cov.com													

CH \$90.00 2015950

900182920

TRADEMARK
REEL: 004465 FRAME: 0742

Correspondent Name: Kathleen T. Gallagher-Duff, Esq.
Address Line 1: 1201 Pennsylvania Avenue, N.W.
Address Line 4: Washington, DISTRICT OF COLUMBIA 20004

ATTORNEY DOCKET NUMBER: 029459.00030

NAME OF SUBMITTER: Cheryl L. Fountain/Paralegal Specialist

Signature: /cheryllfountain/

Date: 02/02/2011

Total Attachments: 3

source=Parkedale Feb 1998 Security Agreement TM Release#page1.tif

source=Parkedale Feb 1998 Security Agreement TM Release#page2.tif

source=Parkedale Feb 1998 Security Agreement TM Release#page3.tif

Release of Security Interest in Trademarks

January 31, 2011

WHEREAS, KING PHARMACEUTICALS, INC., a Tennessee corporation, as Borrower (“King”), certain of its subsidiaries, as Guarantors, and CREDIT SUISSE AG, New York Branch (f/k/a Credit Suisse First Boston, New York Branch) (“**Credit Suisse**”), in its capacity as Collateral Agent for the Secured Parties (as each term is defined in the Security Agreement (as defined below)), entered into that certain Security Agreement dated as of February 27, 1998 (the “**Security Agreement**”);

WHEREAS, the Security Agreement was recorded with the United States Patent and Trademark Office on August 11, 1998 on Reel No. 1767, Frame No. 0665;

WHEREAS, under the Security Agreement, King and Parkedale Pharmaceuticals, Inc. (together, the “**Assignee**”) granted to Credit Suisse a security interest in certain Collateral (as defined in the Security Agreement), including those items set forth on Schedule 1 (collectively, the “**Released Trademark Collateral**”);

WHEREAS, the parties agree and acknowledge that the foregoing United States Patent and Trademark Office assignment record may list Credit Suisse AG in a capacity other than Collateral Agent, and that the security interest was granted to, and this release is correctly made by, Credit Suisse, as Collateral Agent; and

WHEREAS, Credit Suisse desires to release the security interest granted by the Assignee under the Security Agreement in the Released Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Credit Suisse, as Collateral Agent for the Secured Parties, does hereby unconditionally, irrevocably and absolutely terminate, release, extinguish and forever discharge the security interest granted under the Security Agreement in the Released Trademark Collateral, together with all of the goodwill of the business connected with the use of, or symbolized by, such Released Trademark Collateral, and hereby unconditionally, irrevocably and absolutely assigns, transfers and conveys to the Assignee all right, title and interest of Credit Suisse in, to and under such Released Trademark Collateral and such goodwill granted under the Security Agreement. This Release of Security Interest in Trademarks shall be binding upon Credit Suisse’s legal representatives, assigns and successors, and upon the Secured Parties and their legal representatives, assigns and successors. Credit Suisse also hereby authorizes, and requests, the Director of the United States Patent and Trademark Office or his delegate to record this Release of Security Interest in Trademarks against the Released Trademark Collateral.

[signature page to follow]

IN WITNESS WHEREOF, Credit Suisse has caused this Release of Security Interest in Trademarks to be duly executed by its officers thereunto duly authorized as of the day and year first above written.

CREDIT SUISSE AG, NEW YORK BRANCH
(f/k/a Credit Suisse First Boston, New York Branch)

By: 

Name: **KARL M STUDER**

Title: **DIRECTOR**

By: 

Name: **Jay Chall**
Title: **Director**

[signature page – Parkedale Pharmaceuticals, Inc. trademark release]

Schedule 1

KING PHARMACEUTICALS, INC.

U.S. TRADEMARK REGISTRATIONS

Trademark	Registration No.	Registration Date
PROCANBID	2,015,950	November 12, 1996
PROCANBID and Design	2,065,975	May 27, 1997
PROCANBID and Design	2,062,311	May 13, 1997